These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36057415)

  • 1. Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19.
    Kawamata T; Tanino Y; Nikaido T; Minemura H; Sato Y; Togawa R; Watanabe N; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Rikimaru M; Suzuki Y; Tsukada Y; Nakamura K; Kanemitsu K; Iseki K; Shibata Y
    J Infect Chemother; 2022 Dec; 28(12):1639-1644. PubMed ID: 36057415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
    Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
    Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
    Russo G; Solimini A; Zuccalà P; Zingaropoli MA; Carraro A; Pasculli P; Perri V; Marocco R; Kertusha B; Del Borgo C; Del Giudice E; Fondaco L; Tieghi T; D'Agostino C; Oliva A; Vullo V; Ciardi MR; Mastroianni CM; Lichtner M
    PLoS One; 2021; 16(9):e0257376. PubMed ID: 34506608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.
    Moreno Diaz R; Amor García MA; Teigell Muñoz FJ; Saldaña Perez LE; Mateos Gonzalez M; Melero Bermejo JA; López Hernández A; Reyes Marquez L; De Guzman García-Monge MT; Perez Quero JL; Homez Guzman MP
    Eur J Hosp Pharm; 2022 Nov; 29(6):340-345. PubMed ID: 33627476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
    Brosnahan SB; Chen XJC; Chung J; Altshuler D; Islam S; Thomas SV; Winner MD; Greco AA; Divers J; Spiegler P; Sterman DH; Parnia S
    Ann Pharmacother; 2022 Mar; 56(3):237-244. PubMed ID: 34180274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.
    Shastri M; Raval DM; Rathod VM; Patel D
    J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab.
    Sánchez-Montalvá A; Sellarés-Nadal J; Espinosa-Pereiro J; Fernández-Hidalgo N; Pérez-Hoyos S; Salvador F; Durà X; Miarons M; Antón A; Eremiev-Eremiev S; Sempere-González A; Monforte-Pallarés A; Bosch-Nicolau P; Augustin S; Sampol J; Guillén-Del-Castillo A; Almirante B
    Med Clin (Barc); 2022 Jun; 158(11):509-518. PubMed ID: 34544604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
    Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
    Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection.
    Vulturar DM; Neag MA; Vesa ȘC; Maierean AD; Gherman D; Buzoianu AD; Orăsan OH; Todea DA
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab and COVID-19: Timing of administration assessment.
    Richier Q; Jachiet V; Bonnemains V; Plaçais L; Abisror N; Garnier M; Pacanowski J; Dhote R; Hinchschberger O; Michel M; Bienvenu B; Comarmond C; Lacombe K; Mekinian A
    Infect Dis Now; 2022 Feb; 52(1):31-34. PubMed ID: 34198000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.
    Eşkazan AE; Balkan İİ; Demirbaş KC; Ar MC; Karaali R; Sekibağ Y; Mulamahmutoğlu S; Yartaş Dumanlı G; Çakmak F; Özgür Yurttaş N; Kurt F; Aladağ Kurt S; Kuşkucu M; Ürkmez S; Börekçi Ş; Saribal D; Mete B; Bavunoğlu I; Dikmen Y; Aygün G; Midilli K; Tabak F
    J Infect Chemother; 2021 Sep; 27(9):1329-1335. PubMed ID: 34120824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.